Document is current

Article History

Received: 5 January 2023

Accepted: 10 May 2023

First Online: 1 June 2023

Declarations

:

: This case study was approved by Ethics Committee of NTT Medical Center Tokyo prior to the study (approval number: 22‒163). The patient provided written informed consent. Nevertheless, while this manuscript was a case report using data obtained from routine medical care, the study was conducted with full consideration of protecting patient’s personal information according to the guidelines on privacy policy.

: Not applicable.

: HN, YK and MT report no conflict of interest. TK has served on speakers’ bureaus for AstraZeneca K.K., Daiichi Sankyo Co., Ltd., Elmed Eisai Co., Ltd., Kyowa Kirin Co., Ltd., Mochida Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Yakult Honsha Co., Ltd. KU has received research funding from Astellas-Amgen-Biopharma, Otsuka, Apellis, SymBio, Takeda, Nippon Shinyaku, Novartis, AbbVie, Janssen, Bristol Myers Squibb, Ono, Chugai, Daiichi Sankyo, MSD, Astellas, Alexion, Kyowa-Kirin, Gilead, Pfizer, Incyte, SymBio, Celgene, Sumitomo-Dainippon, Mundi, Yakult, and Eisai; and has served on speaker bureaus for Novartis, Astellas, Alexion, Eisai, MSD, Otsuka, Ono, Kyowa-Kirin, Celgene, Daiichi Sankyo, Takeda, Nippon-Shinyaku, PharmaEssentia, Bristol-Myers Squibb, Yakult, Sanofi, Pfizer, Abbvie, and Chugai; and has served on consulting bureaus for Alexion, SymBio, Nippon Shinyaku, Otsuka, Chugai, Sanofi, Takeda, Kyowa-Kirin, Astellas, SOBI, and Alnylam Japan. We have not received any financial support for this report.